Chiesi Group Acquires KalVista Pharmaceuticals for $1.9 Billion
Chiesi Group entered a merger agreement on April 29, 2026, to acquire KalVista Pharmaceuticals, Inc. (KALV) in a deal valued at $1.9 billion. Deal Structure: Chiesi will commence…
Written byAsif SuriaSource: InsideArbitrage
Chiesi Group entered a merger agreement on April 29, 2026, to acquire KalVista Pharmaceuticals, Inc. (KALV) in a deal valued at $1.9 billion. Deal Structure: Chiesi will commence a tender offer to acquire all outstanding shares of KalVista for $27 per share in cash, representing a premium of 40.33% from the stock’s last close. Company